Twist Bioscience (TWST) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Twist Bioscience (NASDAQ:TWST) from a sell rating to a hold rating in a research note published on Thursday morning, Zacks.com reports.

According to Zacks, “Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California. “

TWST stock opened at $27.96 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.43 and a current ratio of 7.72. The firm has a market capitalization of $783.94 million and a PE ratio of -1.10. Twist Bioscience has a twelve month low of $12.38 and a twelve month high of $34.46.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Thursday, February 7th. The company reported ($1.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.33). The firm had revenue of $11.49 million during the quarter, compared to the consensus estimate of $9.70 million. On average, analysts expect that Twist Bioscience will post -4.18 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. FMR LLC acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $26,090,000. Apoletto Ltd acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $10,503,000. BlackRock Inc. acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $7,782,000. Intellectus Partners LLC acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $4,076,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $5,068,000. 22.74% of the stock is currently owned by institutional investors.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Story: Earnings Per Share (EPS) Explained

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply